Jeffrey I Zwicker1,2, Benjamin L Schlechter2, Jack D Stopa1, Howard A Liebman3, Anita Aggarwal4, Maneka Puligandla5, Thomas Caughey6, Kenneth A Bauer1,2, Nancy Kuemmerle7, Ellice Wong8, Ted Wun9, Marilyn McLaughlin10, Manuel Hidalgo2, Donna Neuberg5, Bruce Furie1, Robert Flaumenhaft1. 1. Division of Hemostasis and Thrombosis and. 2. Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA. 3. Jane Anne Nohl Division of Hematology, University of Southern California, Los Angeles, California, USA. 4. Veterans Affairs Medical Center, Washington, DC, USA. 5. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. 6. Mount Auburn Hospital, Cambridge, Massachusetts, USA. 7. White River Junction Veterans Affairs Medical Center, White River Junction, Vermont, USA. 8. Veterans Affairs Connecticut Healthcare System, West Haven, Connecticut, USA. 9. Division of Hematology Oncology, University of California Davis School of Medicine, VA Northern California Health Care System, Sacramento, California, USA. 10. York Hospital, York, Maine, USA.
Abstract
BACKGROUND: Protein disulfide isomerase (PDI) is a thiol isomerase secreted by vascular cells that is required for thrombus formation. Quercetin flavonoids inhibit PDI activity and block platelet accumulation and fibrin generation at the site of a vascular injury in mouse models, but the clinical effect of targeting extracellular PDI in humans has not been studied. METHODS: We conducted a multicenter phase II trial of sequential dosing cohorts to evaluate the efficacy of targeting PDI with isoquercetin to reduce hypercoagulability in cancer patients at high risk for thrombosis. Patients received isoquercetin at 500 mg (cohort A, n = 28) or 1000 mg (cohort B, n = 29) daily for 56 days, with laboratory assays performed at baseline and the end of the study, along with bilateral lower extremity compression ultrasound. The primary efficacy endpoint was a reduction in D-dimer, and the primary clinical endpoint included pulmonary embolism or proximal deep vein thrombosis. RESULTS: The administration of 1000 mg isoquercetin decreased D-dimer plasma concentrations by a median of -21.9% (P = 0.0002). There were no primary VTE events or major hemorrhages observed in either cohort. Isoquercetin increased PDI inhibitory activity in plasma (37.0% in cohort A, n = 25, P < 0.001; 73.3% in cohort B, n = 22, P < 0.001, respectively). Corroborating the antithrombotic efficacy, we also observed a significant decrease in platelet-dependent thrombin generation (cohort A median decrease -31.1%, P = 0.007; cohort B median decrease -57.2%, P = 0.004) and circulating soluble P selectin at the 1000 mg isoquercetin dose (median decrease -57.9%, P < 0.0001). CONCLUSIONS: Isoquercetin targets extracellular PDI and improves markers of coagulation in advanced cancer patients. TRIAL REGISTRATION: Clinicaltrials.gov NCT02195232. FUNDING: Quercegen Pharmaceuticals; National Heart, Lung, and Blood Institute (NHLBI; U54HL112302, R35HL135775, and T32HL007917); and NHLBI Consortium Linking Oncology and Thrombosis (U01HL143365).
BACKGROUND:Protein disulfide isomerase (PDI) is a thiol isomerase secreted by vascular cells that is required for thrombus formation. Quercetin flavonoids inhibit PDI activity and block platelet accumulation and fibrin generation at the site of a vascular injury in mouse models, but the clinical effect of targeting extracellular PDI in humans has not been studied. METHODS: We conducted a multicenter phase II trial of sequential dosing cohorts to evaluate the efficacy of targeting PDI with isoquercetin to reduce hypercoagulability in cancerpatients at high risk for thrombosis. Patients received isoquercetin at 500 mg (cohort A, n = 28) or 1000 mg (cohort B, n = 29) daily for 56 days, with laboratory assays performed at baseline and the end of the study, along with bilateral lower extremity compression ultrasound. The primary efficacy endpoint was a reduction in D-dimer, and the primary clinical endpoint included pulmonary embolism or proximal deep vein thrombosis. RESULTS: The administration of 1000 mg isoquercetin decreased D-dimer plasma concentrations by a median of -21.9% (P = 0.0002). There were no primary VTE events or major hemorrhages observed in either cohort. Isoquercetin increased PDI inhibitory activity in plasma (37.0% in cohort A, n = 25, P < 0.001; 73.3% in cohort B, n = 22, P < 0.001, respectively). Corroborating the antithrombotic efficacy, we also observed a significant decrease in platelet-dependent thrombin generation (cohort A median decrease -31.1%, P = 0.007; cohort B median decrease -57.2%, P = 0.004) and circulating soluble P selectin at the 1000 mg isoquercetin dose (median decrease -57.9%, P < 0.0001). CONCLUSIONS:Isoquercetin targets extracellular PDI and improves markers of coagulation in advanced cancerpatients. TRIAL REGISTRATION: Clinicaltrials.gov NCT02195232. FUNDING: Quercegen Pharmaceuticals; National Heart, Lung, and Blood Institute (NHLBI; U54HL112302, R35HL135775, and T32HL007917); and NHLBI Consortium Linking Oncology and Thrombosis (U01HL143365).
Authors: A Maraveyas; J Waters; R Roy; D Fyfe; D Propper; F Lofts; J Sgouros; E Gardiner; K Wedgwood; C Ettelaie; G Bozas Journal: Eur J Cancer Date: 2011-11-17 Impact factor: 9.162
Authors: Sridhar Kamath; Andrew D Blann; Graham J Caine; David Gurney; Bernard S P Chin; Gregory Y H Lip Journal: Stroke Date: 2002-05 Impact factor: 7.914
Authors: Nick van Es; Martha Louzada; Marc Carrier; Vicky Tagalakis; Peter L Gross; Sudeep Shivakumar; Marc A Rodger; Philip S Wells Journal: Thromb Res Date: 2018-01-09 Impact factor: 3.944
Authors: Jaehyung Cho; Daniel R Kennedy; Lin Lin; Mingdong Huang; Glenn Merrill-Skoloff; Barbara C Furie; Bruce Furie Journal: Blood Date: 2012-05-31 Impact factor: 22.113
Authors: Anish V Sharda; Thomas Bogue; Alexandra Barr; Lourdes M Mendez; Robert Flaumenhaft; Jeffrey I Zwicker Journal: Clin Cancer Res Date: 2021-08-16 Impact factor: 13.801
Authors: Eric Greve; Sergey V Lindeman; Christina Scartelli; Lin Lin; Robert Flaumenhaft; Chris Dockendorff Journal: Org Biomol Chem Date: 2020-08-19 Impact factor: 3.876
Authors: Huriye Ercan; Lisa-Marie Mauracher; Ella Grilz; Lena Hell; Roland Hellinger; Johannes A Schmid; Florian Moik; Cihan Ay; Ingrid Pabinger; Maria Zellner Journal: Cancers (Basel) Date: 2021-05-08 Impact factor: 6.639